RAM Pharmaceuticals

Acyclonine MUM, with its patented delivery process, supports oral comfort and manages localized irritation from oral lesions or ulcerative conditions.

Discover advanced in-office oral lesion treatment for canker sore relief and recurrent aphthous ulcer treatment — empowering dental professionals with chairside therapy for severe mouth ulcer pain relief.

Supportive cancer care solutions for radiation induced oral mucositis treatment and chemotherapy induced oral mucositis management, offering severe oral mucositis therapy and pain relief for head and neck cancer mouth sores and cancer treatment side effect management.

A dental practice reports successful use of Acyclonine MUM for immediate relief of mouth ulcers and lesions, praising its fast action and targeted application.

RAM Pharmaceuticals welcomes Adrienne Rencic, M.D., Ph.D., as Chief Medical Officer, a board-certified dermatologist and physician-scientist.

RAM Therapeutics’ leadership team specializes in clinical drug development and biopharma operations, with expertise in pharmaceuticals, biotechnology, and medical devices.

RAM Therapeutics’ leadership team has decades of experience in pharmaceuticals, technology, and business development, focusing on advancing cancer treatments.

RAM Pharmaceuticals CEO Ricky Myers leads the company’s development of treatments for painful oral lesions and the Cancer Comfort Care initiative, overseeing FDA approval efforts for its products.

RAM Therapeutics offers cancer treatments and partnership opportunities to support cancer patients worldwide.

RAM Therapeutics develops Triamdocaine MUM, a treatment for severe oral mucositis in head and neck cancer patients.

RAM Pharmaceuticals develops, markets, and sells cancer therapy products to the medical industry.